HK1208629A1 - Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency - Google Patents

Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency Download PDF

Info

Publication number
HK1208629A1
HK1208629A1 HK15109368.8A HK15109368A HK1208629A1 HK 1208629 A1 HK1208629 A1 HK 1208629A1 HK 15109368 A HK15109368 A HK 15109368A HK 1208629 A1 HK1208629 A1 HK 1208629A1
Authority
HK
Hong Kong
Prior art keywords
hgh
fusion protein
growth hormone
treatment
hormone deficiency
Prior art date
Application number
HK15109368.8A
Other languages
English (en)
Chinese (zh)
Inventor
L. Cleland Jeffrey
M. Bright George
Humphriss Eric
Schellenberger Volker
Silverman Joshua
P. Stemmer Willem
Wang Chia-Wei
Geething Nathan
Spink Benjamin
Original Assignee
Amunix Operating Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc. filed Critical Amunix Operating Inc.
Publication of HK1208629A1 publication Critical patent/HK1208629A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15109368.8A 2012-06-05 2013-03-14 Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency HK1208629A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261689390P 2012-06-05 2012-06-05
US61/689,390 2012-06-05
US201261663475P 2012-06-22 2012-06-22
US61/663,475 2012-06-22
US201361763753P 2013-02-12 2013-02-12
US61/763,753 2013-02-12
PCT/US2013/031673 WO2013184216A1 (en) 2012-06-05 2013-03-14 Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency

Publications (1)

Publication Number Publication Date
HK1208629A1 true HK1208629A1 (en) 2016-03-11

Family

ID=47998551

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109368.8A HK1208629A1 (en) 2012-06-05 2013-03-14 Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency

Country Status (17)

Country Link
US (2) US20140162949A1 (enExample)
EP (1) EP2858664B1 (enExample)
JP (2) JP2015520188A (enExample)
KR (1) KR20150021072A (enExample)
CN (2) CN107320719A (enExample)
AU (1) AU2013272220A1 (enExample)
BR (1) BR112014030404A2 (enExample)
CA (1) CA2875827A1 (enExample)
DK (1) DK2858664T3 (enExample)
ES (1) ES2733220T3 (enExample)
HK (1) HK1208629A1 (enExample)
IL (1) IL236070A0 (enExample)
MX (1) MX2014014927A (enExample)
NZ (1) NZ702557A (enExample)
PH (1) PH12014502738A1 (enExample)
SG (1) SG11201408152VA (enExample)
WO (1) WO2013184216A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
BR112015022257A8 (pt) * 2013-03-11 2018-01-23 Amunix Operating Inc tratamento de deficiência do hormônio do crescimento pediátrica com análogos de hormônio do crescimento humano
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017136583A1 (en) 2016-02-02 2017-08-10 Versartis, Inc. Growth hormone treatment adherence system
WO2017142331A1 (en) * 2016-02-17 2017-08-24 Genexine, Inc. Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency
RU2732113C2 (ru) * 2016-02-17 2020-09-11 Дженексин, Инк. Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
US20200000884A1 (en) * 2016-07-27 2020-01-02 Amunix Pharmaceuticals, Inc. Treatment of adult growth hormone deficiency with human growth hormone analogues
JOP20190019A1 (ar) 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
CN116554343B (zh) * 2022-01-30 2024-07-12 领诺(上海)医药科技有限公司 一种长效重组人生长激素及其应用
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー,リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CN116003632A (zh) * 2022-12-07 2023-04-25 北京大学 长效缓释型人重组生长激素融合蛋白及其药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EA020843B1 (ru) * 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
LT2440241T (lt) * 2009-06-08 2017-10-10 Amunix Operating Inc. Augimo hormonų polipeptidai ir jų gamybos bei panaudojimo būdai

Also Published As

Publication number Publication date
ES2733220T3 (es) 2019-11-28
AU2013272220A1 (en) 2015-01-15
US20180051063A1 (en) 2018-02-22
EP2858664B1 (en) 2019-05-08
EP2858664A1 (en) 2015-04-15
BR112014030404A2 (pt) 2017-06-27
CN107320719A (zh) 2017-11-07
CN104519903A (zh) 2015-04-15
PH12014502738A1 (en) 2015-02-02
CA2875827A1 (en) 2013-12-12
JP2017125051A (ja) 2017-07-20
IL236070A0 (en) 2015-01-29
WO2013184216A1 (en) 2013-12-12
JP2015520188A (ja) 2015-07-16
SG11201408152VA (en) 2015-01-29
DK2858664T3 (da) 2019-07-08
MX2014014927A (es) 2015-05-15
US20140162949A1 (en) 2014-06-12
KR20150021072A (ko) 2015-02-27
NZ702557A (en) 2017-06-30

Similar Documents

Publication Publication Date Title
HK1208629A1 (en) Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency
IN2012DN06309A (enExample)
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
WO2013059737A3 (en) Tissue treatment device and related methods
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
NZ711373A (en) Fragments of p97 and uses thereof
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
WO2011156286A3 (en) Stimulation therapy for bladder dysfunction
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
PH12014500386A1 (en) Combination treatment for hepatitis c
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
IL309994B1 (en) Optimal peptides targeting human nerves and their use in image-guided surgery, diagnostics and therapeutic delivery
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
UA115250C2 (uk) Фармацевтичні комбінації
EP4361634A3 (en) Methods for treating and monitoring the status of cancer
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
GB201121914D0 (en) Method for patient selection
HK1223630A1 (zh) 抗-egfr疗法的实施与用量
WO2011163512A3 (en) Cancer therapy